

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5448425

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	TREVOR WARREN LISSOOS	04/19/2017
RECEIVING PARTY DATA		
Name:	TAKEDA PHARMACEUTICALS U.S.A., INC.	
Street Address:	ONE TAKEDA PARKWAY	
City:	DEERFIELD	
State/Country:	ILLINOIS	
Postal Code:	60015	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16098572
CORRESPONDENCE DATA		
Fax Number:	(617)535-3800	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6175354453	
Email:	CHEATH@MWE.COM	
Correspondent Name:	KRISTIN A. CONNARN	
Address Line 1:	MCDERMOTT, WILL & EMERY, LLP	
Address Line 2:	500 NORTH CAPITOL STREET, N.W.	
Address Line 4:	WASHINGTON, D.C. 20001-1531	
ATTORNEY DOCKET NUMBER:	079259-0873	
NAME OF SUBMITTER:	KRISTIN A. CONNARN	
SIGNATURE:	/Kristin A. Connarn/	
DATE SIGNED:	03/29/2019	
Total Attachments: 4		
source=079259-0765_ASSIGNMENT_INVENTOR_TO_TAKEDAPHAR#page1.tif		
source=079259-0765_ASSIGNMENT_INVENTOR_TO_TAKEDAPHAR#page2.tif		
source=079259-0765_ASSIGNMENT_INVENTOR_TO_TAKEDAPHAR#page3.tif		
source=079259-0765_ASSIGNMENT_INVENTOR_TO_TAKEDAPHAR#page4.tif		

ASSIGNMENT

WHEREAS, I, **Trevor Warren Lissoos** (Assignor) have made a certain new and useful invention as set forth in an application for Letters Patent of the United States, entitled **TRIPLE COMBINATION THERAPY FOR TREATING INFLAMMATORY BOWEL DISEASE** and filed concurrently herewith; OR for which a patent application for Letters Patent of the United States was filed on **May 4, 2016** and assigned U.S. Patent Application No. **62/221,813**;

AND WHEREAS, **Takeda Pharmaceuticals U.S.A., Inc.** (Assignee), a corporation of the State of Delaware and having an ordinary place of business at **One Takeda Parkway, Deerfield, IL 60015** is desirous of acquiring the entire right, title and interest in and to said invention and in and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, I do hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention and the above-mentioned application for Letters Patent, including any utility applications, continuations, continuations-in-part, and divisions of said application, and in and to any and all Letters Patents of the United States and all foreign countries which may be granted therefore and thereon, and all reissues, re-examinations and extensions thereof, and all rights under any and all international agreements, treaties and laws relating to the protection of industrial property including the right of priority, and the right to apply for and obtain in all countries any and all Letters Patents, and the right to procure the grant of all such Letters Patents to Assignee in its own name, the same to be held and enjoyed by Assignee for its own use and benefit and the use and benefit of its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted and/or extended as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made.

AND UPON SAID CONSIDERATIONS, I hereby agree with the said Assignee that I will not execute any writing or do any act whatsoever conflicting with this grant, and that I will, at any time upon request, without further or additional consideration but at the expense of


said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining utility applications, divisions, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of the United States and any and all foreign countries on said invention, and in enforcing any rights or chose in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the successors, assigns and legal representatives of Assignor and Assignee;

AND I hereby grant Assignee, its legal representatives, successors and assigns, the power to insert on this instrument any further identification that may be necessary or desirable to comply with the recordation rules of any appropriate and competent authority, including, without limitation, the United States Patent and Trademark Office.


AND I hereby agree that this Assignment may be executed in two or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

AND I request the Commissioner for Patents and Trademarks to issue any Letters Patent of the United States which may be issued for said invention and on said application to Assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 19th day of April, 2017.


Trevor Warren Lissos

Witnessed by:


Signature


Date: April 19~~th~~, 2017

Derek Johnson
Typed or Printed Name

1 Takeda Parkway

Deerfield, IL 60015
Witness Address

Witnessed by:


Signature

Date: 19 April 2017

Sara Sarkey
Typed or Printed Name


1 Takeda Parkway

Deerfield, IL 60015
Witness Address

ACCEPTED AND AGREED TO BY ASSIGNEE TAKEDA PHARMACEUTICALS U.S.A.,
Inc.

SIGNED this 19th day of April, 2017.

Takeda Pharmaceuticals U.S.A., Inc.

By: 

Name: Mark J. Buonaiuto

Title: VP & Chief Patent Counsel

DM_US 81331323-1.079259.0765